CA3090330C - Inhibiteur d'atr et son application - Google Patents

Inhibiteur d'atr et son application

Info

Publication number
CA3090330C
CA3090330C CA3090330A CA3090330A CA3090330C CA 3090330 C CA3090330 C CA 3090330C CA 3090330 A CA3090330 A CA 3090330A CA 3090330 A CA3090330 A CA 3090330A CA 3090330 C CA3090330 C CA 3090330C
Authority
CA
Canada
Prior art keywords
compound
group
synthesis
give
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3090330A
Other languages
English (en)
Other versions
CA3090330A1 (fr
Inventor
Wenyuan Qian
Jian Wang
Jie Li
Jian Li
Shuhui Chen
Original Assignee
Wuxi Biocity Biopharmaceutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biocity Biopharmaceutics Co Ltd filed Critical Wuxi Biocity Biopharmaceutics Co Ltd
Priority claimed from PCT/CN2019/074578 external-priority patent/WO2019154365A1/fr
Publication of CA3090330A1 publication Critical patent/CA3090330A1/fr
Application granted granted Critical
Publication of CA3090330C publication Critical patent/CA3090330C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne un composé en tant qu'inhibiteur d'ATR et une application dans la préparation d'un médicament en tant qu'inhibiteur d'ATR. En particulier, l'invention concerne un composé représenté par la formule (I) ou un isomère ou un sel pharmaceutiquement acceptable de celui-ci.
CA3090330A 2018-02-07 2019-02-02 Inhibiteur d'atr et son application Active CA3090330C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810124494 2018-02-07
CN201810124494.2 2018-02-07
CN201811361512.5 2018-11-15
CN201811361512 2018-11-15
PCT/CN2019/074578 WO2019154365A1 (fr) 2018-02-07 2019-02-02 Inhibiteur d'atr et son application

Publications (2)

Publication Number Publication Date
CA3090330A1 CA3090330A1 (fr) 2019-08-15
CA3090330C true CA3090330C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
EP3753937B1 (fr) Inhibiteur d'atr et son application
EP3746435B1 (fr) Dérivés de quinazoline et de pyridopyrimidine substitués utiles en tant qu'agents anticancéreux
CN112442031B (zh) 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
EP1562911B1 (fr) Composes utiles comme inhibiteurs de proteines jak et autres proteines kinase
JP2022527013A (ja) Ｓｈｐ２拮抗薬としてのピリミジノン誘導体
KR102376354B1 (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
TWI660946B (zh) 作為ｍａｇｌ抑制劑之胺基甲酸１，１，１－三氟－３－羥基丙烷－２－酯衍生物
CN115806550B (zh) 双环bet布罗莫结构域抑制剂及其用途
TW202039498A (zh) 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
US20240034743A9 (en) Tricyclic compounds as egfr inhibitors
AU2017323112B2 (en) Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
AU2019344240B2 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
AU2020281411A1 (en) Tetracyclic compounds as Cdc7 inhibitors
KR20220129043A (ko) Hiv 감염의 치료 및 예방을 위한 항바이러스제로서 피리미딘계 바이사이클
JP7340519B2 (ja) ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
JP2024510306A (ja) Ｃｔｌａ－４低分子分解剤及びその使用
RU2799047C2 (ru) Ингибитор atr и его применение
BR112020016020B1 (pt) Composto inibidor de atr e seus usos
KR20250148666A (ko) Sgk1의 억제제로서의 아미노-치환된 피롤로트리아진 유도체
HK40036987A (en) Atr inhibitor and application thereof
HK40036987B (en) Atr inhibitor and application thereof
TW202607004A (zh) ６，７－二氫－５Ｈ－吡咯並〔１，２ａ〕咪唑類衍生物及其製備方法和用途
CN119119085A (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
BR112020001124A2 (pt) composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto ou do sal farmaceuticamente aceitável do mesmo e método para tratamento de câncer
BR112020001124B1 (pt) Composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e uso do composto ou do sal farmaceuticamente aceitável do mesmo